At a glance
ClinicalIndex Comparison RecordPhase 1Not Yet Recruiting· 20 target
Drug / intervention
Ziftomenib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 1/1b Trial Of Olutasidenib And Ziftomenib For NPM1 And IDH1 Co-Mutated Acute Myeloid Leukemia
In Brief
A Phase 1 clinical trial evaluating Ziftomenib and Olutasidenib for Acute Myeloid Leukemia. Not yet recruiting, targeting 20 participants across 1 site.
Detailed Summary
The goal of Phase 1 is to find the recommended dose of ziftomenib and olutasidenib in patients with relapsed/refractory AML that has a mutation in the NPM1 and IDH1 genes. The goal of Phase 1b is to learn if the recommended dose of ziftomenib and olutasidenib found in Phase 1 can help to control the disease. The safety and effects of this combination will also be studied in both parts.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Myeloid Leukemia
CountriesUnited States
Collaborators--
Timeline
Phase 1Not Yet Recruiting
202720282029
First PostedFeb 2026
TodayJul 2026
Enrollment StartAug 2026
Primary CompletionJan 2027
Study CompletionJan 2029
First PostedFeb 17, 2026
Enrollment StartAug 31, 2026
Primary CompletionJan 14, 2027
Study CompletionJan 14, 2029
TodayJul 1, 2026
Enrollment to primary: 4 monthsPosted 4 months agoPrimary completion in 6 months
Interventions
Ziftomenibdrug
Given by mouth
Olutasidenibdrug
Given by mouth